Real-World Study of Ceftazidime Avibactam in China — REACT  

Hospital Acquired Pneumonia Clinical Trial

Official title: Real-World Study of Ceftazidime-Avibactam to Characterize the Usage in Clinical Practice

Status Recruiting

Clinical Trial Summary

This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.

Clinical Trial Description

The recruitment will last for approximately 6 months or until recruitment target is met, and information about treatment will be collected from the patients' medical records. Patients will be followed from CAZ AVI initiation until death, withdraw of the study, 60 days after discharged from the hospitalization, whichever comes first. The endpoint events will be evaluated at: 7 days, 14 days, 21 days, 30 days, 60 days, and end of treatment (EOT) after CAZ AVI initiation, if patients are not discharged prior to the next upcoming timepoint; and 30 days, 60 days after discharge. ;

Related Conditions & MeSH terms

• Complicated Intra Abdominal Infections
• Healthcare-Associated Pneumonia
• Hospital Acquired Pneumonia
• Intraabdominal Infections
• Pneumonia
• Pneumonia, Ventilator-Associated
• Ventilator Acquired Pneumonia

• NCT number: NCT05487586
• Study type: Observational
• Source: Pfizer
• Contact: Pfizer CT.gov Call Center
• Phone: 1-800-718-1021
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Status: Recruiting
• Start date: October 20, 2022
• Completion date: August 30, 2024